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Abstract
Background Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque pso-
riasis patients.
Objective To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics.
Methods In this multicentre study, psoriasis patients (N = 262) treated with an anti-TNF-alpha agent, ustekinumab or
na€ıve to biologics then switched to adalimumab were included. Disease severity was assessed by the Psoriasis Area
and Severity Index (PASI) at baseline and after 3, 6, 12, 24 and 36 months. The association between clinical risk factors
and achievement of PASI response was evaluated by logistic regression.
Results Adalimumab treatment resulted in a decrease in PASI (15.1  6.2 at baseline vs. 2.7  4.8 at 6 months,
P < 0.0001), regardless of previous biologic treatment. Furthermore, adalimumab allowed 92.5%, 79% and 56% of
patients to achieve PASI response (PASI 50, 75 and 90, respectively) and complete remission (PASI 100 response) in
48.4% of patients, by 6 months and maintained over 3 years, independent of prior biologic treatment. The absence of
metabolic syndrome, dyslipidemia, hypertension and lower PASI and lower age at baseline was associated with achieve-
ment of PASI response at 3, 6 and 12 months, whereas at later time points (24 and 36 months), PASI 90 and PASI 100
response was associated with diagnosis of psoriasis/psoriatic arthritis.
Conclusion Adalimumab was effective at reducing PASI score over 3 years, irrespective of whether patients were bio-
logic na€ıve or previously treated with a TNF-alpha or IL-12/23 inhibitor.
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Introduction
Psoriasis is characterized as a chronic inflammatory autoim-
mune skin disease with a prevalence of 1–3% worldwide.1 The
most frequent form of psoriasis, plaque psoriasis is (approxi-
mately 90% of patients) characterized by painful and itchy ery-
thematous plaques localized on the elbows and knees and scalp
or generalized disease across wider areas of the body.2,3 Approxi-
mately 25 million patients worldwide are affected by severe-to-
moderate psoriasis, defined as a PASI score >10 or BSA >10%
and DLQI >10.3 This severe form of psoriasis usually requires
treatment with systemic medications or phototherapy.4
For the past few decades, treatment of this disease has
included traditional systemic drugs; (e.g. methotrexate, aci-
tretin and cyclosporine) however, their use is hampered by*These authors contributed equally to this paper and conceived this study.
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intolerance or organ-specific toxicity, particularly following
long-term use.5
National and International Guideline Treatment strategies of
severe or refractory/recalcitrant psoriasis are based on disease-
modifying antirheumatic drugs (DMARDs), such as methotrexate
and cyclosporine.6,7 In cases of inadequate response, contraindi-
cation or intolerance to at least one DMARD, a therapy with a
biologic drug such as tumour necrosis factor (TNF)-alpha inhibitors
(e.g. adalimumab, infliximab or etanercept) or anti-interleukin
therapies (ustekinumab, secukinumab, ixekizumab and bro-
dalumab) is recommended.5–12 Although these treatments are
effective in treating psoriasis (without severe adverse events),
between 10% and 30% of patients show inadequate response,
necessitating switching to a second-line biologic.13 In real-life
clinical practice, switching is relatively common; however, few
studies have evaluated the efficacy of secondary biologic treat-
ment in these patients.14,15
Adalimumab is a TNF-alpha inhibitor indicated for the treat-
ment of psoriasis and psoriatic arthritis and several randomized
controlled trials and meta-analysis studies have demonstrated
short- and long-term benefit.16–23 Less understood, however, is
whether the extent of benefit granted by adalimumab is similar
in patients previously treated with another biologic agent, par-
ticularly in the real-life setting.22
The purpose of this study was to evaluate the effect of adali-
mumab treatment in moderate-to-severe psoriasis on PASI
response in patients na€ıve to biologics or in patients previously
treated with a different anti-TNF-alpha agent or previously trea-
ted with the IL-12/23 inhibitor ustekinumab. The association
between dependent variables (clinical characteristics, comorbidi-
ties and risk factors for psoriasis) associated with achievement of
PASI response was also evaluated.
Materials and methods
Patients and study design
Outcome of Psoriatic Patients Switched to Adalimumab
(OPPSA) was a retrospective longitudinal non-interventional
epidemiological investigation performed by consulting a clinical
database of psoriasis patients (with or without psoriatic arthri-
tis) consecutively arriving for their routine visit. Patients were
being treated with biologic drugs in five centres of the Lazio
region of Italy between 1 January 2010 and 31 December 2015.
Inclusion criteria included male or female patients diagnosed
with moderate-severe psoriasis and/or psoriatic arthritis treated
with adalimumab (using standard dosing regimen as prescribed
within the EU24) for at least 16 weeks from 1 January 2010 to 31
December 2015 after conventional or biologic therapy; patients
≥18 years of age and having signed an informed consent form
and having undertaken at least two specialist visits for treatment
of psoriasis during the 16 weeks after initiating adalimumab
treatment. Reasons for switching to adalimumab were inefficacy,
intolerance or presence of adverse events and included a wash-
out period of approximately 1 month, according to clinical
practice guidelines.3 Reasons for suspension of adalimumab
treatment were primary inefficacy (failure to achieve PASI 50
after 12 weeks of treatment) or secondary inefficacy (loss of
PASI 50 after 12 weeks of treatment) in patients without arthri-
tis only. Exclusion criteria included patients with other autoim-
mune/inflammatory diseases such as Crohn’s disease, ulcerative
colitis, rheumatoid arthritis and ankylosing spondylitis; patients
treated with a biologic <16 weeks or patients that had received
systemic treatment or phototherapy in combination with bio-
logic agent within 4 weeks of the first visit. Diagnosis of psoriasis
was clinical. Demographic and anamnestic data, comorbidities,
current and previous biologic treatments and Psoriasis Area
Severity Index (PASI) score at the moment of enrolment were
recorded using a dedicated database. Ethics committee approval
from all five participating centres and written informed consent
was obtained from all patients. This study complies with the eth-
ical standards laid down in the 1975 Declaration of Helsinki.
Outcome measures
To evaluate the efficacy of adalimumab, the 50%, 75%, 90% and
100% improvement in PASI score (PASI 50, 75, 90 and 100) was
calculated at the moment of enrolment and compared to values
prior to undergoing treatment (baseline values). Secondary end-
points were to evaluate the potential effect of previous anti-
TNF-alpha treatment (e.g. etanercept, infliximab, golimumab),
anti-interleukin treatment (e.g. ustekinumab) or biologic naive
patients on PASI response (50, 75, 90 and 100) following adali-
mumab treatment over the 3-year follow-up. The association
between dependent variables (age, sex, height, waist circumfer-
ence, HLA-C*06:02 status, PASI at baseline, age of onset of pso-
riasis, disease duration, presence of hypertension, diabetes,
dyslipidemia, metabolic syndrome, smoking history, alcohol
intake, use of adalimumab as first biologic, number of anti-
TNF-alpha drugs used before adalimumab, use of ustekinumab
before adalimumab) and achievement of PASI 50, 75, 90 and
100 at 3, 6, 12, 24 and 36 months was also evaluated.
DNA extraction and HLA typing
Venous blood for genotyping was collected in EDTA tubes and
stored at 70°C. Genomic DNA was isolated from whole blood
using DNAeasy blood and tissue kit (Qiagen, Inc., Hilden,
Germany). The HLA-C*06:02 locus was detected by standard
polymerase chain reaction (PCR) using the allele-specific pri-
mers: forward 50-TACTACAACCAGAGCGAGGA-30 and reverse
50-GGTCGCAGCCATACATCCA-30, as previously described.25
Statistical analysis
Data are presented as mean  SD for continuous variables, and
number and percentage for categorical variables. Comparisons
between groups were performed by the chi-squared test for
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categorical variables and the one-way analysis of variance or
Wilcoxon test for continuous variables. Stepwise multivariate
logistic regression models were performed to evaluate the associ-
ation between dependent variables (e.g. clinical characteristics
and risk factors for presence of psoriasis) and achievement of
PASI 50, 75, 90 and 100 at 3, 6, 12, 24 and 36 months. In the
case of missing data, the last observation carried forward method
(LOCF: if a patient dropped out of the study the last value avail-
able was ‘carried forward’ until the end of the treatment).26
P < 0.05 was considered statistically significant. All analysis was
performed using Stata 13 (Statacorp LP Inc., College Station,
TX, USA).
Results
Patient demographic and clinical characteristics
A total of 262 patients with psoriasis were included in the
OPPSA study. Patient clinical and demographic characteristics
are summarized in Table 1. Approximately 63% of patients were
male (mean age of 52.1  14.3 years), with psoriasis disease
duration of 18  12 years and mean baseline PASI score of
15.1  6.2. Of the 262 patients, 88 (33.6%) also had psoriatic
arthritis and 66 (25.2%) had hypertension. Clinical characteris-
tics of patients among the three treatment groups (na€ıve to bio-
logics before adalimumab treatment, anti-TNF-alpha agent
before adalimumab and ustekinumab prior to adalimumab)
revealed some differences (Table 1). Patients previously treated
with anti-TNF-alpha agents had elevated BMI (28  7.9 vs.
25.6  4.5 in ustekinumab-treated patients, P < 0.05) and
higher prevalence of psoriatic arthritis (62.9% vs. 18.5% in
ustekinumab-treated patients, P < 0.0001). In contrast, patients
treated with ustekinumab before switching to adalimumab had
lower psoriasis familiarity (31.5% vs. 68.5% in anti-TNF-alpha-
treated patients, P < 0.0001), slightly higher baseline PASI
(17.3  8.7 vs. 14.2  5.2 in anti-TNF-alpha-treated patients,
P < 0.05) and higher burden of comorbid diseases (59.3% vs.
41.6% in patients na€ıve to biologics, P < 0.05). Although these
differences were statistically significant, other clinically relevant
variables such as age, gender and disease duration were similar
among the different groups.
PASI response
Mean PASI was significantly decreased in all patients following
adalimumab treatment over the follow-up period (Fig. 1a).
Compared to baseline levels (15.1  6.2), PASI declined by 12.4
points to 2.7  4.8 by 6 months. This reduction was maintained
for the remainder of the 3-year follow-up period (Fig. 1a). Adal-
imumab also granted a high proportion of patients to achieve
PASI 50, 75 and 90 (92.5%, 79% and 56%, respectively) and
complete remission (PASI 100 response) in 48.4% of patients, by
6 months (Fig. 1b). We next wanted to evaluate whether a dif-
ferential effect on PASI improvement could be observed follow-
ing adalimumab treatment among the three groups. Mean PASI
was significantly decreased compared to baseline values in all
three groups, with no difference observed among them (Fig. 2a).
Although not attaining statistical significance, PASI was
decreased to a greater extent in biologic na€ıve patients over the
follow-up period (Fig. 2a). A similar profile was observed when
Table 1 Clinical characteristics of psoriasis patients
Anti-TNF agent Total
(N = 262)
Naive
(n = 154)
Anti-TNF ? Ada
(n = 54)
Uste ? Ada
(n = 54)
P-value†
Male patients, n (%) 166 (63.3) 97 (62.9) 34 (62.96) 32 (59.3) 0.88
Age (years) 52.1  14.3 51.1  14.9 55.1  12.7 50.5  12.2 0.15
BMI (kg/m2) 26.2  4.4 26.3  4.1 28  7.9 vs. UA* 25.6  4.5 0.043
Current smoker 115 (44.2) 69(44.8) 30 (55.6) 19 (35.2) 0.1
Alcohol consumption 89 (33.96) 53 (34.4) 22 (40.7) 14 (25.9) 0.26
Psoriasis familiarity, n (%) 150 (57.3) 93 (60.4) 37 (68.5) 17 (31.5) vs. N+TA**** 0.0001
Psoriatic arthritis, n (%) 88 (33.6) 44 (28.6) 34 (62.9) 10 (18.5) vs. TA**** <0.0001
Disease duration (years) 18  12 16.7  10.2 17.9  12.8 19.8  11.6 0.2
PASI (baseline) 15.1  6.2 14.5  5.8 14.2  5.2 17.3  8.7 vs. N+TA* 0.013
Comorbidities, n (%) 125 (47.7) 64 (41.6) 29 (53.7) 32 (59.3) vs. N* 0.049
Hypertension 66 (25.2) 34 (22.1) 16 (29.6) 16 (29.6) 0.28
Dyslipidemia 45 (17.2) 22 (14.3) 8 (14.8) 15 (27.8) 0.068
Diabetes 43 (16.4) 21 (13.6) 13 (24.1) 9 (16.7) 0.2
Cardiovascular disease 20 (7.6) 9 (5.8) 9 (16.7) 2 (3.7) vs. TA* 0.017
Metabolic syndrome 18 (6.9) 6 (3.9) 4 (7.4) 8 (14.8) vs. N** 0.024
BMI, body mass index; PASI, Psoriasis area severity index; Ada, adalimumab; Uste, ustekinumab.
Data are presented as mean  SD or number (%). N refers to number of patients.
†P-values refer to statistically significant differences among the three groups (naive, N; anti-TNF ? Ada; TA, Uste ? Ada; UA) by one-way ANOVA.
Comparison between specific groups by Bonferroni post hoc analyses among specific groups are indicated where *<0.05, **<0.01, ***<0.001 and ****<0.0001.
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the effect of adalimumab on PASI response was compared
among the three groups (Fig. 2b–e, Table 2). A lower propor-
tion of patients previously treated with ustekinumab before
being switched to adalimumab achieved PASI 50 (86.7% at
12 months) and PASI 75 response (82.2%), compared to a more
favourable improvement observed over the study period in both
anti-TNF ? adalimumab (96.1% and 88.2%, respectively) and
biologic na€ıve patients (95.8% and 86%, respectively; Fig. 2b,c).
Approximately 65% of all patients achieved a PASI 90 response
by 3 years and a similar proportion of biologic na€ıve patients
achieved complete remission by 3 years, although this response
was slightly lower (about 45%) in the anti-TNF ? adalimumab
and ustekinumab ? adalimumab groups (Fig. 2e).
Association between dependent variables on PASI
response
A stepwise logistic regression model was used to evaluate the
association between a range of dependent variables (complete list
of variables provided in Methods) and achievement of PASI 50,
75, 90 and 100 at 3, 6, 12, 24 and 36 months of adalimumab
treatment. No significant difference was observed in terms of
response rate between the group of patients treated in first-line
with adalimumab (biologic na€ıve) and patients treated with other
anti-TNF-alpha agents (e.g. infliximab or etanercept) before adal-
imumab treatment or patients treated with ustekinumab before
starting adalimumab treatment. However, several dependent vari-
ables were observed to be significantly associated with an
improvement in PASI response at specific time points (Table 3).
Multivariate analysis revealed that the absence of metabolic syn-
drome, dyslipidemia, hypertension, lower PASI and lower age at
baseline was associated with achievement of PASI response (PASI
50, 75, 90 and 100) at 3, 6 and 12 months. In contrast, at later
time points (24 and 36 months), a diagnosis of psoriasis and con-
comitant psoriatic arthritis was associated with an approximately
threefold increase in odds of achievement of PASI 90 and PASI
100 response, regardless of baseline disease severity (Table 3).
Discussion
Results from the OPPSA provide evidence that adalimumab can
be considered as an optimal therapeutic choice in psoriatic
patients over the long term, regardless of their prior exposure to
biologics.
The short- and long-term benefit of adalimumab for the treat-
ment of psoriasis and psoriatic arthritis is well established from
several randomized controlled trials and meta-analyses.16–23
However, little evidence is available documenting the effect of
adalimumab administered as second-line biologic treatment
compared to first-line treatment in the real-life setting.22
Our findings revealed that adalimumab permitted 92.5%,
79% and 56% of patients to achieve PASI 50, 75 and 90,
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Figure 1 Effect of adalimumab in psoriatic patients (N = 262) on
PASI score and achievement of PASI 50, 75, 90 and 100 response.
(a) PASI is presented as mean values. Error bars represent SD. (b)
PASI response is presented as % patients achieving PASI 50, 75,
90 and 100 response.
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Figure 2 Effect of adalimumab in psoriatic patients naive to bio-
logics, previously treated with another anti-TNF-alpha agent and
patients previously treated with ustekinumab on PASI score and
achievement of PASI 50, 75, 90 and 100 response. (a) PASI is pre-
sented as mean values. (b–e) PASI response is presented as %
patients achieving PASI 50, 75, 90 and 100 response.
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respectively) and complete remission (PASI 100 response) in just
under half (48.4%) of patients by 6 months, this benefit being
maintained over the 3-year follow-up. These improvements in
PASI are in line with those reported in clinical trials.16–23,27 Our
efficacy results closely reflect values observed after 4 months of
adalimumab treatment in 100 psoriatic patients in daily practice
by Arnesto et al.22 for PASI 50, PASI 90 and PASI 100 (85.7%,
78.7% and 40%, respectively). Furthermore, no significant dif-
ference was observed between efficacy in patients previously
na€ıve vs. those not na€ıve to biologics in this study.22 Similar
findings were observed by van L€umig et al.28 in 85 patients trea-
ted with adalimumab for 1.4 years. Although PASI 75 response
at 3 months was significantly higher in biologic na€ıve (56%) vs.
non-na€ıve (29%) patients, no difference was observed at later
time points. Our study confirms these results and extends them
further by demonstrating that previous biologic therapy does
not influence the efficacy of adalimumab in the short (up to
6 months) as well as long term (up to 3 years).
Variability in treatment efficacy of adalimumab has been
observed among these controlled and real-life studies, and causal
factors have already been identified.22,28–32 While no difference
was observed in terms of PASI response between biologic na€ıve,
previous anti-TNF-alpha or previous ustekinumab treatment on
the effect of adalimumab, stepwise logistic regression in our
study revealed that younger patients, no diabetes/metabolic syn-
drome, no dyslipidemia, no hypertension or a lower PASI at
baseline were significantly associated with better achievement of
PASI response by 3 and 6 months. Interestingly, at later time
points (1, 2 and 3 years), absence of hypertension and a positive
diagnosis for psoriasis/psoriatic arthritis were significantly asso-
ciated with increased odds of achieving PASI 90 and complete
remission (PASI 100).
It is recognized that switching is prescribed at a moment
when patients are doing relatively poorly and will probably do
better again at a later time point, termed a regression-like
effect.33 Although previous analysis of psoriasis patients has
identified several factors as being associated with response to
biologics, information is still scarce on predictor variables for
treatment response over the long term.34 Our analysis identified
that patients without diabetes/metabolic syndrome were associ-
ated with better achievement of PASI response, particularly in
the first 6 months following adalimumab treatment. Actually,
moderate-to-severe psoriasis is frequently associated with the
metabolic syndrome and its disorders such as type 2 diabetes,
dyslipidemia and obesity.35,36 The underlying mechanisms
affecting the efficacy of adalimumab in psoriasis patients with
Table 2 PASI response rate for psoriasis patients to adalimumab treatment and over the 3-year follow-up period
PASI response Follow-up (months)
3 months 6 months 12 months 24 months 36 months
All psoriasis patients
N (%) 255 252 239 227 166
PASI 50 226 (88.6) 233 (92.5) 219 (91.6) 206 (90.8) 151 (91.2)
PASI 75 127 (49.8) 199 (79) 200 (83.7) 194 (85.3) 140 (84.1)
PASI 90 83 (32.5) 141 (56) 150 (62.8) 150 (66.1) 108 (64.8)
PASI 100 54 (21.2) 122 (48.4) 137 (57.3) 134 (59.2) 90 (54.2)
Biologic naive patients
N (%) 150 151 143 142 112
PASI 50 134 (89.3) 142 (94) 137 (95.8) 138 (97.2) 108 (96.4)
PASI 75 75 (50) 122 (80.8) 123 (86) 127 (89.4) 106 (94.6)
PASI 90 50 (33.3) 88 (58.3) 95 (66.4) 98 (69) 77 (68.8)
PASI 100 45 (30) 83 (55) 92 (64.3) 89 (62.7) 73 (65.2)
Anti-TNF ? adalimumab patients
N (%) 52 52 51 48 34
PASI 50 44 (84.9) 49 (94.2) 49 (96.1) 45 (93.8) 32 (94.1)
PASI 75 26 (50.9) 43 (82.7) 45 (88.2) 43 (89.6) 30 (88.2)
PASI 90 18 (34) 27 (51.9) 29 (56.9) 29 (60.4) 21 (61.8)
PASI 100 13 (24.5) 23 (44.2) 28 (54.9) 24 (50) 15 (44.1)
Ustekinumab ? adalimumab patients
N (%) 53 49 45 37 20
PASI 50 44 (83) 43 (87.8) 39 (86.7) 31 (83.8) 18 (90)
PASI 75 23 (43.4) 35 (71.4) 37 (82.2) 29 (78.4) 17 (85)
PASI 90 16 (30.2) 27 (55.1) 29 (64.4) 25 (67.6) 14 (70)
PASI 100 12 (22.6) 20 (40.8) 22 (48.9) 17 (45.9) 9 (45)
N, number of patients; PASI, Psoriasis area severity index.
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the metabolic syndrome are still poorly understood; however,
studies exploring the genetic predispositions of patients may
provide insight as to why patients respond to one biologic but
not another.34 While the presence of the HLA-C*06:02 polymor-
phism in psoriatic patients has been shown to be associated with
the efficacy of other biologics,25 our group has previously
demonstrated that the effect of adalimumab treatment was not
associated with this allele.37 Similarly, in the present study,
HLA-C*06:02 allele was not found to be associated with PASI
response at any of the time points examined. However, a diagno-
sis of psoriatic arthritis (combined with psoriasis) emerged from
our multivariate analysis as being strongly associated with com-
plete PASI remission in the long term (1- to 3-year follow-up).
This association has also been previously observed32 but a
negative association has already been implicated.31 However,
these studies were limited by short follow-up and small sample
sizes.
The efficacy of anti-TNF-alpha biologics is also known to be
reduced in patients with elevated BMI and in elderly patients.38–
40 While BMI did not emerge as a predictor for improved PASI
response, lower age at baseline was found to be significantly
associated with improved PASI response with the first month of
treatment. A pattern also emerged from our analysis whereby
predictors of an improvement in PASI response in the short
term predominantly included absence of metabolic syndrome,
absence of dyslipidemia and lower age at baseline, whereas long-
term treatment improvement was mainly associated with psoria-
sis and psoriatic arthritis diagnosis. These temporal differences
remain to be examined further in a larger sample size with
longer follow-up to ascertain whether the presence of early
metabolic and late articular involvement may play an important
role in the therapeutic management of these patients. Taken
together, these results confirm that adalimumab is a valid thera-
peutic option for the management of severe-to-moderate plaque
psoriasis (with or without psoriatic arthritis), as recommended
by National guidelines and International guidelines.6,7
Limitations
There are some potential limitations that need to be addressed.
Weaknesses of observational registries such as the reliability of
results and incompleteness of data have already been estab-
lished.41,42 Furthermore, the lack of randomization may have
also introduced selection bias, and the presence of other unmea-
sured confounders may have been missed in our analysis. Patient
adherence was not the aim of this study and was therefore not
evaluated. Some differences in baseline characteristics among
patients previously treated with different biologics were noted. A
higher proportion of psoriatic arthritis patients were observed in
the anti-TNF-alpha group (62.9%) compared to biologic na€ıve
(28.6%) and ustekinumab group (18.5%). This may be due to
the fact that anti-TNF-alpha biologics have shown greater
improvement in psoriatic arthritis patients compared to ustek-
inumab.29
However, stepwise logistic regression analysis adjusted for
baseline PASI or presence of psoriatic arthritis therefore preclud-
ing these variables as being attributed to any potential bias.
Conclusion
Findings from the present study demonstrate that adalimumab
granted a significantly high proportion of patients to achieve
PASI 50, 75 and 90 (92.5%, 79% and 56%, respectively) and
complete remission (PASI 100 response; 48.4% of patients), by
6 months. This improvement in PASI response was maintained
up to 3 years. The effect of adalimumab was independent of
prior biologic treatment or type of biologic previously used
(anti-TNF-alpha or IL12/23). Real-world data represent an
Table 3 Stepwise multivariate logistic regression analysis of
dependent variables associated with achievement of PASI
response at different time points
PASI response rate OR (95% CI) P-value
PASI 50
3 months
Metabolic syndrome (absence) 0.15 (0.05–0.44) <0.0001
PASI 75
3 months
Dyslipidemia (absence) 0.29 (0.12–0.69) 0.006
Metabolic syndrome (absence) 0.11 (0.014–0.94) 0.043
PASI 90
3 months
Dyslipidemia (absence) 0.088 (0.02–0.37) 0.001
Lower PASI at baseline 0.93 (0.89–0.99) 0.014
6 months
Lower age at baseline 0.98 (0.96–0.99) 0.024
Metabolic syndrome (absence) 0.34 (0.11–0.99) 0.05
12 months
Hypertension (absence) 0.29 (0.15–0.56) <0.0001
Diagnosis of PsA and PsO 2.5 (1.3–4.9) 0.008
PASI 100
3 months
Dyslipidemia (absence) 0.054 (0.007–0.4) 0.005
Lower PASI at baseline 0.89 (0.83–0.95) <0.0001
6 months
Lower age at baseline 0.97 (0.95–0.99) 0.001
Lower PASI at baseline 0.93 (0.89–0.98) 0.004
12 months
Hypertension (absence) 0.39 (0.2–0.75) 0.005
Diagnosis of PsA and PsO 2.9 (1.5–5.6) 0.001
24 months
Diagnosis of PsA and PsO 2.9 (1.4–5.9) 0.004
36 months
Diagnosis of PsA and PsO 3.5 (1.3–4.9) 0.008
BMI, body mass index; CI, confidence interval; NI, variables not included in
multivariate model; OR, odds ratio; PASI, Psoriasis area severity index; PsA,
psoriatic arthritis; PsO, psoriasis.
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important source of information to determine the efficacy of dif-
ferent biologic agents currently available in day-to-day condi-
tions of clinical practice and among heterogeneous groups of
patients, typically excluded from randomized controlled trials.
Findings from the OPPSA study will aid dermatologists in their
choice of biologic for the treatment of psoriasis patients. Addi-
tional studies are still needed to assess the differential effective-
ness of biologic agents as rescue therapy in the case of primary
or secondary failure over the long term.
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